A single, high priming dose of tremelimumab added to Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful overall survival benefit versus Nexavar (sorafenib) as a first-line treatment for patients with unresectable hepatocellular carcinoma who had not received prior systemic therapy and were not eligible for localized treatment.
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
